Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer


Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.

Related Videos
Related Content